Expression of USP22 and the chromosomal passenger complex is an indicator of malignant progression in oral squamous cell carcinoma

Liu,Tian; Liu,Jing; Chen,Qiuyue; Jin,Shengjian; Mi,Sisi; Shao,Wenhua; Kudo,Yasusei; Zeng,Sien; Qi,Guangying

doi:10.3892/ol.2018.9837

Expression of USP22 and the chromosomal passenger complex is an indicator of malignant progression in oral squamous cell carcinoma

Authors:
- Tian Liu
- Jing Liu
- Qiuyue Chen
- Shengjian Jin
- Sisi Mi
- Wenhua Shao
- Yasusei Kudo
- Sien Zeng
- Guangying Qi
View Affiliations

Affiliations: Department of Pathology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China, Department of Pathology and Physiopathology, Guilin Medical University, Guilin, Guangxi 541004, P.R. China, Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770‑8504, Japan
Published online on: December 17, 2018 https://doi.org/10.3892/ol.2018.9837
Pages: 2040-2046
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral cancer is a common cancer of the head and neck. Oral squamous cell carcinoma (OSCC) represents almost 90% of the total cases of head and neck cancer. Ubiquitin‑specific protease 22 (USP22) is a deubiquitinating hydrolase, and it is highly expressed in various types of cancer, which also typically have a poor prognosis. Aurora‑B and Survivin, which belong to the chromosomal passenger complex, are also highly expressed in a number of types of cancer. In the present study, USP22 expression and its associations with Aurora‑B and Survivin, and the clinicopathological features in OSCC were explored. USP22 is highly expressed in OSCC. Overexpression of USP22 is associated with lymph node metastasis and histological grade (P<0.01). Additionally, the expression of USP22 was positively associated with Aurora‑B (P<0.01), Survivin (P<0.01), and Ki‑67 (P<0.01). Furthermore, USP22 small interfering RNA inhibited cell growth and reduced the expression levels of Aurora‑B, Survivin and Cyclin B, together with the upregulation of cyclin‑dependent kinase inhibitor 1A (p21). These data suggest that USP22, Aurora‑B and Survivin promote the OSCC development and may represent novel targets for OSCC diagnosis and treatment in the future.

View Figures

View References

1	Wikner J, Gröbe A, Pantel K and Riethdorf S: Squamous cell carcinoma of the oral cavity and circulating tumor cells. World J Clin Oncol. 5:114–124. 2014. View Article : Google Scholar : PubMed/NCBI
2	Mascitti M, Orsini G, Tosco V, Monterubbianesi R, Balercia A, Putignano A, Procaccini M and Santarelli A: An overview on current non-invasive diagnostic devices in oral oncology. Front Physiol. 9:15102018. View Article : Google Scholar : PubMed/NCBI
3	Amerik AY and Hochstrasser M: Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta. 1695:189–207. 2004. View Article : Google Scholar : PubMed/NCBI
4	Zhang XY, Pfeiffer HK, Thorne AW and McMahon SB: USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle. 7:1522–1524. 2008. View Article : Google Scholar : PubMed/NCBI
5	Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL and McMahon SB: The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
6	Jordan CT: Cancer stem cell biology: From leukemia to solid tumors. Curr Opin Cell Biol. 16:708–712. 2004. View Article : Google Scholar : PubMed/NCBI
7	Tang B, Liang X, Tang F, Zhang J, Zeng S, Jin S, Zhou L, Kudo Y and Qi G: Expression of USP22 and survivin is an indicator of malignant behavior in hepatocellular carcinoma. Int J Oncol. 47:2208–2216. 2015. View Article : Google Scholar : PubMed/NCBI
8	Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM and Baek KH: The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns. 6:277–284. 2006. View Article : Google Scholar : PubMed/NCBI
9	Glinsky GV, Berezovska O and Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar : PubMed/NCBI
10	Lv L, Xiao XY, Gu ZH, Zeng FQ, Huang LQ and Jiang GS: Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem. 346:11–21. 2011. View Article : Google Scholar : PubMed/NCBI
11	Liu YL, Yang YM, Xu H and Dong XS: Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. J Surg Oncol. 103:283–289. 2011. View Article : Google Scholar : PubMed/NCBI
12	Luo Y, Zeng FQ, Gu ZH, Wang L, Wang ZY, Jiang GS and Xiao XY: Quantitative analysis of the putative cancer stem cell marker USP22 mRNA in the transitional cell carcinoma of the bladder and the relationship between USP22 and the grading of tumor. J Clin Urol. 24:140–144. 2009.
13	Carmena M, Wheelock M, Funabiki H and Earnshaw WC: The chromosomal passenger complex (CPC): From easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol. 13:789–803. 2012. View Article : Google Scholar : PubMed/NCBI
14	Van der Waal MS, Hengeveld RC, van der Horst A and Lens SM: Cell division control by the chromosomal passenger complex. Exp Cell Res. 318:1407–1420. 2012. View Article : Google Scholar : PubMed/NCBI
15	Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003. View Article : Google Scholar : PubMed/NCBI
16	Vong QP, Cao K, Li HY, Iglesias PA and Zheng Y: Chromosome alignment and segregation regulated by ubiquitination of survivin. Science. 310:1499–1504. 2005. View Article : Google Scholar : PubMed/NCBI
17	Zhao Y, Lang G, Ito S, Bonnet J, Metzger E, Sawatsubashi S, Suzuki E, Le Guezennec X, Stunnenberg HG, Krasnov A, et al: A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell. 29:92–101. 2008. View Article : Google Scholar : PubMed/NCBI
18	Sun Z, Hu S, Luo Q, Ye D, Hu D and Chen F: Overexpression of SENP3 in oral squamous cell carcinoma and its association with differentiation. Oncol Rep. 29:1701–1706. 2013. View Article : Google Scholar : PubMed/NCBI
19	Barnes L, Eveson JW, Reichart P and Sidransky D: Pathology and genetics of head and neck tumours. IARC Press. World Health Organization Classification of Tumours. 168–175. 2005.
20	Liu YL, Zheng J, Tang LJ, Han W, Wang JM, Liu DW and Tian QB: The deubiquitinating enzyme activity of USP22 is necessary for regulating HeLa cell growth. Gene. 572:49–56. 2015. View Article : Google Scholar : PubMed/NCBI
21	Maerki S, Olma MH, Staubli T, Steigemann P, Gerlich DW, Quadroni M, Sumara I and Peter M: The Cul3-KLHL21 E3 ubiquitin ligase targets aurora B to midzone microtubules in anaphase and is required for cytokinesis. J Cell Biol. 187:791–800. 2009. View Article : Google Scholar : PubMed/NCBI
22	Qi G, Tuncel H, Aoki E, Tanaka S, Oka S, Kaneko I, Okamoto M, Tatsuka M, Nakai S and Shimamoto F: Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep. 22:557–562. 2009.PubMed/NCBI
23	Qi G, Kudo Y, Ando T, Tsunematsu T, Shimizu N, Siriwardena SB, Yoshida M, Keikhaee MR, Ogawa I and Takata T: Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol. 46:263–270. 2010. View Article : Google Scholar : PubMed/NCBI
24	Tuncel H, Shimamoto F, Kaneko Guangying Qi H, Aoki E, Jikihara H, Nakai S, Takata T and Tatsuka M: Nuclear Aurora B and cytoplasmic Survivin expression is involved in lymph node metastasis of colorectal cancer. Oncol Lett. 3:1109–1114. 2012. View Article : Google Scholar : PubMed/NCBI
25	Hori M, Miki T, Okamoto M, Yazama F, Konishi H, Kaneko H, Shimamoto F, Ota T, Temme A and Tatsuka M: The detergent-soluble cytoplasmic pool of survivin suppresses anoikis and its expression is associated with metastatic disease of human colon cancer. PLoS One. 8:e557102013. View Article : Google Scholar : PubMed/NCBI
26	Qi G, Ogawa I, Kudo Y, Miyauchi M, Siriwardena BS, Shimamoto F, Tatsuka M and Takata T: Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch. 450:297–302. 2007. View Article : Google Scholar : PubMed/NCBI
27	Qi G, Mi S, Jin S, Shao W, Liu J, Liu T, Zeng S and Lu H: The role of the cancer stem cell marker USP22 in tumors. Stem Cell Trans Invest. 3:e12192016.
28	Kurai M, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H, Suzuki A and Konishi I: Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol. 36:1281–1288. 2005. View Article : Google Scholar : PubMed/NCBI
29	Nguyen HG, Chinnappan D, Urano T and Ravid K: Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: Identification of an aneuploidy-promoting property. Mol Cell Biol. 25:4977–4992. 2005. View Article : Google Scholar : PubMed/NCBI